News

The company said that BMS-663068 is an oral prodrug of the molecule BMS-626529 and first-in-class HIV-1 attachment inhibitor. BMS-663068 is designed to work differently than entry inhibitors, a

Dosing in this multi-center, open-label, dose-escalation trial has been carried out by the University of Virginia School of Medicine. The company is conducting the trial in collaboration with

The company said that ISIS-HTT is the first therapy to enter clinical development that is designed to directly target the cause of the disease by reducing the production

MGB-BP-3 is an antibiotic that has been shown to be active against a broad range of important multi-resistant Gram-positive pathogens. The company has developed the oral formulation of

The study will use Forge’s expertise and intellectual property in the field of metalloprotein inhibitor discovery, while the company will receive funding support from JRD. Forge Therapeutics CEO

As part of the deal, both the firms will carry out collaborative research using the J-Brain Cargo technology and certain pharmaceutical candidate compounds of Eisai’s choice, to develop

Asahi has the rights to develop and market Xiaflex in Japan through an agreement with BioSpecifics’ partner Endo International (Endo). In return, BioSpecifics will be eligible for receiving

The trial is designed to evaluate both the safety and efficacy of human neural stem cells for the treatment of geographic atrophy (GA), the most advanced form of

Intrahepatic cholangiocarcinoma (ICC), a sub-category of cholangiocarcinoma, is a tumor in the bile duct that arises within the liver and it is the second most common primary liver